NCT06136598View on ClinicalTrials.gov

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

November 14, 2025

Study Completion Date

March 14, 2027

Conditions
Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

Opevesostat

Tablets to be taken orally.

DRUG

Dexamethasone

Tablets to be taken orally

DRUG

Fludrocortisone

Tablets to be taken orally.

DRUG

Hydrocortisone

Tablet to be taken orally as a rescue medication.

Trial Locations (3)

100034

Peking University First Hospital-Urology ( Site 0001), Beijing

430000

Tongji Hospital Tongji Medical,Science & Technology ( Site 0002), Wuhan

510700

Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003), Guangzhou

All Listed Sponsors
collaborator

Orion Corporation, Orion Pharma

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06136598 - A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) | Biotech Hunter | Biotech Hunter